$MGX

Reid Laurence purchased $23K of MGX

Reid Laurence purchased 20,000 shares of Metagenomi Therapeutics, Inc. (MGX) at an average of $1.17 ($1.17–$1.18) across 2 trades on 2026-09-09.

Original reporting
SEC EDGAR · Reid Laurence
Published Sep 11, 2026, 11:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 11:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MGX
Neutral
low confidence
Mentioned
$MGX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MGXNeutralLow
01

Why it matters

The transaction is modest and unlikely to move the stock, but it provides a data point for tracking insider sentiment.

02

Market read

Low relevance; a routine insider purchase with minimal market impact.

03

What to watch

Potential upcoming clinical data or partnership announcements could give context to the purchase.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 disclosures are primary sources for insider transactions. This filing reports a director's purchase of MGX shares.

Company-level read

Ticker impact

$MGXNeutralLow confidence
Context

Director Reid Laurence bought 20,000 shares for $23,401, a Form 4 filing disclosed today.

Expected impact

Minimal impact; likely no immediate price movement.

Evidence & confidence

Purchase amount is modest ($23K) and unlikely to affect market perception.

Market effects

None; isolated insider transaction.

None; company is US‑listed biotech.

None

Counterpoint

Even small insider buys can precede larger moves; monitor for follow‑on activity.

Key entities

  • Metagenomi Therapeutics, Inc.

    Biotech firm developing microbiome‑based therapies, ticker MGX.

  • Reid Laurence

    Director of Metagenomi Therapeutics.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MGXMed

Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Metagenomi Therapeutics, Inc. (MGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results Remains on track to submit investigational new drug (IND) application in 4Q 2026 for the global clinical program of MGX-001 for the treatment of hemophilia A $120.7 million in

$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).